Rare Disease Diagnostics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027 Segmented By Indication (Gastroenterology Disease, Endocrine & Metabolism Disorders Disease, Cardiovascular Disorders, Hematology & Oncology Disease, Others), By Trait Type (Inherited v/s Acquired), By Test Type (Genetic Tests, General Lab Tests, Diagnostic Imaging, Others), By Technology (N
Published on: 2024-11-23 | No of Pages : 320 | Industry : Healthcare
Publisher : MIR | Format : PDF&Excel
Rare Disease Diagnostics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027 Segmented By Indication (Gastroenterology Disease, Endocrine & Metabolism Disorders Disease, Cardiovascular Disorders, Hematology & Oncology Disease, Others), By Trait Type (Inherited v/s Acquired), By Test Type (Genetic Tests, General Lab Tests, Diagnostic Imaging, Others), By Technology (N
The global rare disease diagnostics market is anticipated to observe impressive growth during the forecast period, 2023-2027. The major factors include growing incidence of rare disorders, adoption of advanced technology, and increase in investments in R&D are impelling the growth of the market. Rare diseases or orphan diseases is any disease that affect a small percentage of the population. The other factors supporting the market’s growth are, increasing government initiatives for spreading awareness, expanding patient registry for rare disease, declining sequencing cost, rising geriatric population, growing launch of programs & new product development in rare disease diagnosis, and rise in research and development activities.
Rising incidence of rare disorders will fuel the market growth
Technological Advancements in Disease Diagnosis
Rising Awareness of diagnosis of rare diseases
For instance, every year, rare diseases day at NIH takes place which aims to raise awareness about rare diseases and the impact they have on patients’ lives.
Market Segmentation
Market Players
Agilent Technologies, Inc., Illumina, Inc., QIAGEN NV, PerkinElmer, Inc, Quest Diagnostics, Inc., CENTOGENE N.V., 23andMe, Inc., 3billion, Inc., Eurofins Scientific SE, and Invitae Corporation
| Attribute | Details |
| Base Year | 2021 |
| Historic Data | 2017 – 2020 |
| Estimated Year | 2022 |
| Forecast Period | 2023 – 2027 |
| Quantitative Units | Revenue in USD Million, Volume Units and CAGR for 2017-2021 and 2022-2027 |
| Report coverage | Revenue forecast, Volume forecast company share, competitive landscape, growth factors, and trends |
| Segments covered | · Indication · Trait Type · Test Type · Technology · Sample Type · End User · Company |
| Regional scope | North America; Asia Pacific; Europe & CIS; South America; Middle East & Africa |
| Country scope | United States; Canada; Mexico; China; India; Japan; South Korea; Germany; France; United Kingdom; Spain; Italy; Brazil; Argentina; Colombia; South Africa; UAE; Saudi Arabia; South Africa |
| Key companies profiled | Agilent Technologies, Inc., Illumina, Inc., QIAGEN NV, PerkinElmer, Inc, Quest Diagnostics, Inc., CENTOGENE N.V., 23andMe, Inc., 3billion, Inc., Eurofins Scientific SE, and Invitae Corporation |
| Customization scope | 10% free report customization with purchase. Addition or alteration to country, regional & segment scope. |
| Pricing and purchase options | Avail customized purchase options to meet your exact research needs. Explore purchase options |
| Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |